BOOK ONLINE

Please select the service you would like to book:

search-button

MSI Reproductive Choices UK statement on decision by the High Court not to restrict abortion access in cases of foetal anomaly

Press releases  •  23 September 2021  • 1 min read

Share






Copied


Media Statement

London, 23rd September 2021 

If you are covering today’s decision by the High Court not to restrict abortion access in cases of foetal anomaly, you may find the following statement from MSI Reproductive Choices UK helpful.

Louise McCudden, MSI Reproductive Choices’ UK Advocacy and Public Affairs Adviser said:

“We welcome today’s High Court ruling. Deciding whether to continue with a pregnancy or not is sometimes a complex, personal decision, and people can need time to consider their options carefully, with all the available information. As a pro-choice organisation, we strongly support a compassionate, information-led approach to this deeply sensitive issue, rather than greater restrictions on abortion rights.”

“We support calls for up to date, accurate, non-stigmatising information about Down’s Syndrome to be made available to anyone who is considering an abortion on this basis. We also support and trust the person who is pregnant to then make whatever decision is best for themselves and their family free from judgement.”

For further information please contact:

Email: [email protected]

Telephone: +44 (0) 7769 166 516


Share






Copied

Related posts

News


17 April 2023  • 4 min read

New research highlights the importance of choice in abortion care

New research highlights how underinvestment and lack of training are impacting choice in abortion care.

News


22 June 2023  • 4 min read

MSI Comment on Abortion Statistics for England and Wales: January to June 2022

Our summary of the 2022 abortion statistics for England and Wales.

News


9 July 2021  • 2 min read

MSI Reproductive Choices UK comment on the reclassification of the progestogen-only pill

Media statement London, 9th July 2021 If you are covering the reclassification of the progestogen-only